The American College of Obstetricians and Gynecologists (ACOG) issued a response to an August letter from misoprostol manufacturer Searle that warned against using the drug in pregnant women. Misoprostol is used in conjunction with mifepristone as a form of early, non-surgical abortion, and this combination has been used in France and other countries for over a decade. The US Food and Drug Administration (FDA) approved mifepristone for use in conjunction with misoprostol as a form of early abortion on September 28. ACOG chair of obstetrics Charles Lockwood stated, according to National Public Radio, “After reviewing all the information that the FDA has accumulated, we find no reason to change our practice habits, we find no explanation for the Searle letter, and no real explanation for the timing of the Searle letter.” ACOG Also sent copies of the letter to Representatives Tom Coburn (R-OK) and Tim Hutchinson (R-AR), who cited Searle’s “warning” when introducing a bill to restrict women’s access to mifepristone.
Uncategorized
